Literature DB >> 14697644

Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia.

Elisabet Lloveras1, Isabel Granada, Lurdes Zamora, Blanca Espinet, Lourdes Florensa, Carles Besses, Marisol Xandri, Maria Encarnación Pérez-Vila, Fuensanta Millà, Soledad Woessner, Francesc Solé.   

Abstract

We report cytogenetic results in a series of 60 patients affected with multiple myeloma (MM) and plasma cell leukemia (PCL) and compare the results with those previously reported. In our series, a total of 41% of MM patients and 71% of PCL patients displayed chromosome abnormalities. To evaluate the clinical value of monosomy 18, we obtained fluorescence in situ hybridization results (using centromeric probe for chromosome 18) of 22 MM patients who displayed a normal karyotype. Monosomy 18 was present in 3 of 22 patients (14%). Using conventional cytogenetics, we detected monosomy 18 in one patient affected with PCL. Two of four cases with monosomy 18 followed an aggressive course, with overall survival of 1 and 9 months. The remaining two are in follow-up and remain stable. The association of monosomy 18 with IgA subtype predominance and poor prognosis was not observed in this series of MMs and PCLs. Although these results do not confirm our previous hypothesis, further observations of this group of patients (with monosomy 18) regarding malignant transformation is warranted.

Entities:  

Mesh:

Year:  2004        PMID: 14697644     DOI: 10.1016/s0165-4608(03)00233-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

Review 1.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 2.  Plasma cell leukemia.

Authors:  Flavio Albarracin; Rafael Fonseca
Journal:  Blood Rev       Date:  2011-02-03       Impact factor: 8.250

3.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

Review 4.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

5.  Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.

Authors:  Alexey Zatula; Aida Dikic; Celine Mulder; Animesh Sharma; Cathrine B Vågbø; Mirta M L Sousa; Anders Waage; Geir Slupphaug
Journal:  Oncotarget       Date:  2017-03-21

6.  Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.

Authors:  Hasna Hamdaoui; Oumaima Benlarroubia; Oum Kaltoum Ait Boujmia; Hossein Mossafa; Karim Ouldim; Aziza Belkhayat; Imane Smyej; Houda Benrahma; Hind Dehbi; Fatima Chegdani
Journal:  Mol Genet Genomic Med       Date:  2020-06-23       Impact factor: 2.183

7.  Profile of Chromosomal Alterations, Chromosomal Instability and Clonal Heterogeneity in Colombian Farmers Exposed to Pesticides.

Authors:  María Paula Meléndez-Flórez; Duvan Sebastián Valbuena; Sebastián Cepeda; Nelson Rangel; Maribel Forero-Castro; María Martínez-Agüero; Milena Rondón-Lagos
Journal:  Front Genet       Date:  2022-02-24       Impact factor: 4.599

8.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.